Clinical Trial Participation: Representation Matters
As science and medicine continue to develop at a rapid pace, clinical trial participation is more important than ever in helping to develop potential medicines that are safer and more effective for the people they intend to treat.
Who Should Participate in Clinical Trials?
At the heart of all clinical trials are the people who participate in them. Race, ethnicity, age, and sex can all impact how different people respond to the same medicine or vaccine. This is why diversity among clinical trial participants is so important. The more diverse a group of clinical trial participants, the more we can learn about the safety and efficacy of a potential medicine for people who have characteristics like those of the participants.
When individuals choose to participate in a clinical trial, they will represent people from their local communities — in age, race, ethnicity, and sex. Participation in clinical trials by people of all backgrounds can make a difference by reducing health disparities among underrepresented populations and improving the development of medicines and vaccines for everyone.
In the United States, African American men have a higher mortality rate from prostate cancer compared to men of other races. While the reasons behind the difference in mortality rate continue to be studied, African American men in prostate cancer research remains of highest importance. Diverse participation is necessary to ensure potential new and developing medicines are safe and effective for all men.
Ensuring diversity in clinical trials is a matter of equity. Everyone deserves a chance to raise their hand and participate and contribute. The choice to participate in a clinical trial is a personal one and should be made in consultation with your doctor and your support network, including family and friends.
Clinical Trial Opportunity
The TALAPRO-3 clinical trial is enrolling men with metastatic castration-sensitive prostate cancer (mCSPC) who also have DNA repair defects. The goal of TALAPRO-3 is to understand if the study drug (talazoparib) when taken with an existing treatment approved for metastatic prostate cancer (enzalutamide) can help keep the cancer under control for longer than taking enzalutamide alone.
If you would like to know more about the TALAPRO-3 clinical trial or are interested in taking part, visit www.Talapro3ClinicalTrial.com.
This content is brought to you by Pfizer.